gyki 52466 has been researched along with Ischemic Attack, Transient in 7 studies
GYKI 52466: an AMPA (non-NMDA) receptor antagonist; structure given in first source
Ischemic Attack, Transient: Brief reversible episodes of focal, nonconvulsive ischemic dysfunction of the brain having a duration of less than 24 hours, and usually less than one hour, caused by transient thrombotic or embolic blood vessel occlusion or stenosis. Events may be classified by arterial distribution, temporal pattern, or etiology (e.g., embolic vs. thrombotic). (From Adams et al., Principles of Neurology, 6th ed, pp814-6)
| Excerpt | Relevance | Reference |
|---|---|---|
| "GYKI 52466 failed to inhibit this increase." | 1.29 | Effect of the non-NMDA receptor antagonist GYKI 52466 on the microdialysate and tissue concentrations of amino acids following transient forebrain ischaemia. ( Arvin, B; Chapman, AG; Graham, JL; Lekieffre, D; Meldrum, BS; Moncada, C, 1994) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 6 (85.71) | 18.2507 |
| 2000's | 1 (14.29) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Elger, B | 1 |
| Huth, A | 1 |
| Neuhaus, R | 1 |
| Ottow, E | 1 |
| Schneider, H | 1 |
| Seilheimer, B | 1 |
| Turski, L | 1 |
| Li, H | 1 |
| Buchan, AM | 1 |
| Arvin, B | 3 |
| Lekieffre, D | 1 |
| Graham, JL | 1 |
| Moncada, C | 3 |
| Chapman, AG | 1 |
| Meldrum, BS | 3 |
| Weiser, T | 1 |
| Brenner, M | 1 |
| Palluk, R | 1 |
| Bechtel, WD | 1 |
| Ceci, A | 1 |
| Brambilla, A | 1 |
| Ensinger, HA | 1 |
| Sagrada, A | 1 |
| Wienrich, M | 1 |
| Gyertyán, I | 1 |
| Gigler, G | 1 |
| Simó, A | 1 |
| Le Peillet, E | 2 |
| Chapman, A | 1 |
7 other studies available for gyki 52466 and Ischemic Attack, Transient
| Article | Year |
|---|---|
Novel alpha-amino-3-hydroxy-5-methyl-4-isoxazole propionate (AMPA) receptor antagonists of 2,3-benzodiazepine type: chemical synthesis, in vitro characterization, and in vivo prevention of acute neurodegeneration.
Topics: Acute Disease; Animals; Benzodiazepines; Binding, Competitive; Brain Infarction; Cells, Cultured; Di | 2005 |
Treatment with an AMPA antagonist 12 hours following severe normothermic forebrain ischemia prevents CA1 neuronal injury.
Topics: alpha-Amino-3-hydroxy-5-methyl-4-isoxazolepropionic Acid; Animals; Anti-Anxiety Agents; Benzodiazepi | 1993 |
Effect of the non-NMDA receptor antagonist GYKI 52466 on the microdialysate and tissue concentrations of amino acids following transient forebrain ischaemia.
Topics: Amino Acids; Animals; Anti-Anxiety Agents; Aspartic Acid; Benzodiazepines; Cerebral Cortex; Corpus S | 1994 |
BIIR 561 CL: a novel combined antagonist of alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptors and voltage-dependent sodium channels with anticonvulsive and neuroprotective properties.
Topics: alpha-Amino-3-hydroxy-5-methyl-4-isoxazolepropionic Acid; Animals; Anti-Anxiety Agents; Anticonvulsa | 1999 |
The neuroprotective and hypothermic effect of GYKI-52466, a non-competitive alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid-antagonist on histological and behavioural variables in the gerbil global ischemia model.
Topics: Animals; Anti-Anxiety Agents; Benzodiazepines; Body Temperature; Chlorpromazine; Excitatory Amino Ac | 1999 |
The non-NMDA antagonists, NBQX and GYKI 52466, protect against cortical and striatal cell loss following transient global ischaemia in the rat.
Topics: Animals; Anti-Anxiety Agents; Benzodiazepines; Cell Death; Cerebral Cortex; Corpus Striatum; Excitat | 1992 |
GYKI 52466 blocks the increase in extracellular glutamate induced by ischaemia.
Topics: Animals; Anti-Anxiety Agents; Benzodiazepines; Cerebral Cortex; Corpus Striatum; Glutamates; Glutami | 1992 |